CoChat

The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results

Open access
Khanani, Arshad M., Aziz, Aamir A., Khan, Hannah, Gupta, Ashwin, Mojumder, Ohidul, Saulebayeva, Aigerim, Abbey, Ashkan M., Almeida, David R. P., Avery, Robert L., Banda, Himanshu K., Barakat, Mark R., Bhandari, Ramanath, Chang, Emmanuel Y., Haug, Sara J., London, Nikolas J. S., Mein, Luke, Sheth, Veeral S., Wolfe, Jeremy D., Singer, Michael A., Danzig, Carl J. · 2023 · Eye
Cited by 180

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Background/Objective: Investigate real-world patients receiving faricimab for the treatment of neovascular age-related macular degeneration (nAMD). Subjects/Methods: Multicenter, retrospective chart review was conducted on patients treated with faricimab for nAMD from February 2022 to September 2022. Collected data includes background demographics, treatment history, best-corrected visual acuity (BCVA), anatomic changes, and adverse events as safety markers. The main outcome measures are changes in BCVA, changes in central subfield thickness (CST) and adverse events. Secondary outcome measures included treatment intervals and presence of retinal fluid. Results: After one injection of faricimab, all eyes (n = 376), previously-treated (n = 337) and treatment-naïve (n = 39) eyes demonstrated a + 1.1 letter (p = 0.035), a + 0.7 letter (p = 0.196) and a + 4.9 letter (p = 0.076) improvement in BCVA, respectively, and a − 31.3 μM (p < 0.001), a − 25.3 μM (p < 0.001) and a − 84.5 μM (p < 0.001) reduction in CST, respectively. After three injections of faricimab, all eyes (n = 94), previously-treated (n = 81) and treatment-naïve (n = 13) eyes demonstrated a + 3.4 letter (p = 0.03), a + 2.7 letter (p = 0.045) and a + 8.1 letter (p = 0.437) improvement in BCVA, and a − 43.4 μM (p < 0.001), a − 38.1 μM (p < 0.001) and a − 80.1 μM (p < 0.204) reduction in CST, respectively. One case of intraocular inflammation was observed after four injections of faricimab and resolved with topical steroids. One case of infectious endophthalmitis was treated with intravitreal antibiotics and resolved. Conclusions: Faricimab has demonstrated improvement or maintenance of visual acuity for patients with nAMD, along with rapid improvement of anatomical parameters. It has been well-tolerated with low incidence of treatable intraocular inflammation. Future data will continue to investigate faricimab for real-world patients with nAMD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41433-023-02553-5

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Metadata

Authors
Khanani, A. M., Aziz, A. A., Khan, H., Gupta, A., Mojumder, O., Saulebayeva, A., Abbey, A. M., Almeida, D. R. P., Avery, R. L., Banda, H. K., Barakat, M. R., Bhandari, R., Chang, E. Y., Haug, S. J., London, N. J. S., Mein, L., Sheth, V. S., Wolfe, J. D., Singer, M. A., & Danzig, C. J.
Venue
Eye
Published
2023-05-12
Volume
37
Issue
17
Pages
3574-3581
ISSN
  • 0078-5334 (ISSN-L)
  • 0950-222X
  • 1476-5454
OpenAlex
W4376276190
Cited by
180
References
7
FWCI
36.90
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results. https://app.cochat.ai/papers/10.1038/s41433-023-02553-5
The paper
Khanani, A. M., Aziz, A. A., Khan, H., Gupta, A., Mojumder, O., Saulebayeva, A., Abbey, A. M., Almeida, D. R. P., Avery, R. L., Banda, H. K., Barakat, M. R., Bhandari, R., Chang, E. Y., Haug, S. J., London, N. J. S., Mein, L., Sheth, V. S., Wolfe, J. D., Singer, M. A., & Danzig, C. J. (2023). The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results. Eye. https://doi.org/10.1038/s41433-023-02553-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.